U.S. Brain Tumor Market Size, Share & Trends Analysis Report By Tumor Type (Malignant, Non-malignant), By Treatment Type (Surgery, Radiation Therapy, Interventional Device-Based Procedures, Chemotherapy), And Segment Forecasts, 2025 - 2034

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research in the U.S.
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Tumor Type outlook
  • 2.2.2. Treatment Type outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Brain Tumor Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of primary and secondary brain tumors
    • 3.2.1.2. Innovations in diagnostic imaging, surgical techniques (such as advanced neurosurgery), and therapeutic modalities (such as targeted therapies, immunotherapies, and radiotherapy)
    • 3.2.1.3. Increasing awareness and early diagnosis of brain tumor
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High treatment costs
    • 3.2.2.2. Side effects and complications associated with brain tumor treatrment
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Increasing number of clinical trials
    • 3.2.3.2. Rising fundings and investments from both public and private sectors in research and development activities
  • 3.2.4. Market challenge analysis
    • 3.2.4.1. Product recalls
    • 3.2.4.2. Stringent regulations
• 3.3. U.S. Brain tumor Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Brain Tumor Market: Tumor Type Estimates & Trend Analysis

• 4.1. Definitions and Scope
• 4.2. Tumor Type Market Share, 2024 & 2034
• 4.3. Segment Dashboard
• 4.4. U.S. Brain Tumor Market by Tumor Type Outlook
• 4.5. Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients Undergo Treatment Per Tumor Type)
  • 4.5.1. Malignant
    • 4.5.1.1. Malignant market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.1.2. Glioblastomas
      • 4.5.1.2.1. Glioblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.1.3. Medulloblastomas
      • 4.5.1.3.1. Medulloblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.1.4. Astrocytomas
      • 4.5.1.4.1. Astrocytomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.1.5. Ependymomas
      • 4.5.1.5.1. Ependymomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.1.6. Others
      • 4.5.1.6.1. Others market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
  • 4.5.2. Non-Malignant
    • 4.5.2.1. Non-Malignant market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.2.2. Meningiomas
      • 4.5.2.2.1. Meningiomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.2.3. Pituitary Adenomas
      • 4.5.2.3.1. Pituitary Adenomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.2.4. Craniopharyngiomas
      • 4.5.2.4.1. Craniopharyngiomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.2.5. Hemangioblastomas
      • 4.5.2.5.1. Hemangioblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.2.6. Others
      • 4.5.2.6.1. Others market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)

Chapter 5. U.S. Brain Tumor Market: Treatment Type Estimates & Trend Analysis

• 5.1. Definitions and Scope
• 5.2. Treatment Type Market Share, 2024 & 2030
• 5.3. Segment Dashboard
• 5.4. U.S. Brain Tumor Market by Treatment Type Outlook
• 5.5. Malignant Tumor Treatment Type Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients per Treatment), USD Million in Terms of Number of Patients per Treatment, Volume (Unit)
  • 5.5.1. Surgery
    • 5.5.1.1. Surgery market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 5.5.1.2. Neurosurgical Instruments
      • 5.5.1.2.1. Neurosurgical instruments market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.1.3. Robotic Surgery Systems
      • 5.5.1.3.1. Robotic surgery systems market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.1.4. Interventional Device-Based Procedures
      • 5.5.1.4.1. Interventional device-based procedures market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.1.5. Endoscopes
      • 5.5.1.5.1. Endoscopes market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.1.6. Intraoperative Imaging Systems
      • 5.5.1.6.1. Intraoperative imaging systems market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.1.7. Others
      • 5.5.1.7.1. Others market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.2. Radiation Therapy
    • 5.5.2.1. Radiation therapy market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.2.2. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices
      • 5.5.2.2.1. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.2.2.2. Linear Accelerators (LINAC)
        • 5.5.2.2.2.1. Linear Accelerators (LINAC) market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.2.2.3. Gamma Knife Systems
        • 5.5.2.2.3.1. Gamma knife systems market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.2.2.4. Proton radiosurgery
        • 5.5.2.2.4.1. Proton radiosurgery market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.2.3. Internal radiation/Brachytherapy devices
      • 5.5.2.3.1. Internal radiation/brachytherapy devices market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.3. Interventional Device-Based Procedures
    • 5.5.3.1. Interventional device-based procedures market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.3.2. Embolization Devices
      • 5.5.3.2.1. Embolization devices market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.3.2.2. Liquid Embolic Agents
        • 5.5.3.2.2.1. Liquid embolic agents market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.3.2.3. Microspheres
        • 5.5.3.2.3.1. Microspheres market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.3.3. Tumor Ablation Devices
      • 5.5.3.3.1. Tumor ablation devices market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.4. Chemotherapy
    • 5.5.4.1. Chemotherapy market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.5. Targeted Therapy
    • 5.5.5.1. Targeted therapy market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.6. Tumor Treating Fields (TTF)
    • 5.5.6.1. Tumor Treating Fields (TTF) market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.7. Laser Interstitial Thermal Therapy (LITT)
    • 5.5.7.1. Laser Interstitial Thermal Therapy (LITT) market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.8. Surgically Targeted Radiation Therapy
    • 5.5.8.1. Surgically targeted radiation therapy market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.9. Catheter-Based Ultrasound Thermal Ablation
    • 5.5.9.1. Catheter-based ultrasound thermal ablation market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.10. Focused Ultrasound (FUS)
    • 5.5.10.1. Focused Ultrasound (FUS) market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.11. Low-Intensity Focused Ultrasound (LIFU)
    • 5.5.11.1. Low-Intensity Focused Ultrasound (LIFU) market estimates and forecast 2024 to 2034 (USD Million)
• 5.6. Non-Malignant Tumor Treatment Type Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients per Treatment), USD Million in Terms of Number of Patients per Treatment, Volume (Unit)
  • 5.6.1. Surgery
    • 5.6.1.1. Surgery market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 5.6.1.2. Neurosurgical Instruments
      • 5.6.1.2.1. Neurosurgical instruments market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.2.2. Blade, Knife, Cutter & Scissors
        • 5.6.1.2.2.1. Blade, knife, cutter & scissors market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.2.3. Dissector
        • 5.6.1.2.3.1. Dissector market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.2.4. Drill & Perforator
        • 5.6.1.2.4.1. Drill & perforator market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.2.5. Others
        • 5.6.1.2.5.1. Others market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.1.3. Robotic Surgery Systems
      • 5.6.1.3.1. Robotic surgery systems market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.1.4. Endoscopes
      • 5.6.1.4.1. Endoscopes market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.1.5. Intraoperative Imaging Systems
      • 5.6.1.5.1. Intraoperative imaging systems market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.1.6. Others
      • 5.6.1.6.1. Others market estimates and forecast 2024 to 2034 (USD Million)
  • 5.6.2. Radiation Therapy
    • 5.6.2.1. Radiation Therapy market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.2.2. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices
      • 5.6.2.2.1. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.2.2.2. Linear Accelerators (LINAC)
        • 5.6.2.2.2.1. Linear Accelerators (LINAC) market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.2.2.3. Gamma Knife Systems
        • 5.6.2.2.3.1. Gamma knife systems market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.2.2.4. Proton radiosurgery
        • 5.6.2.2.4.1. Proton radiosurgery market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.2.3. Internal radiation/Brachytherapy Devices
      • 5.6.2.3.1. Internal radiation/brachytherapy devices market estimates and forecast 2024 to 2034 (USD Million)
  • 5.6.3. Other Monitoring Devices
    • 5.6.3.1. Other monitoring devices market estimates and forecast 2024 to 2034 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
  • 6.2.1. Innovators
• 6.3. Vendor Landscape
  • 6.3.1. List of key distributors and channel partners
  • 6.3.2. Key customers
  • 6.3.3. Key company market share analysis, 2024
  • 6.3.4. GT Medical Technologies, Inc.
    • 6.3.4.1. Company overview
    • 6.3.4.2. Financial performance
    • 6.3.4.3. Product benchmarking
    • 6.3.4.4. Strategic initiatives
  • 6.3.5. Novocure
    • 6.3.5.1. Company overview
    • 6.3.5.2. Financial performance
    • 6.3.5.3. Product benchmarking
    • 6.3.5.4. Strategic initiatives
  • 6.3.6. ZAP Surgical Systems, Inc.
    • 6.3.6.1. Company overview
    • 6.3.6.2. Financial performance
    • 6.3.6.3. Product benchmarking
    • 6.3.6.4. Strategic initiatives
  • 6.3.7. Aesculap, Inc. - a B. Braun company
    • 6.3.7.1. Company overview
    • 6.3.7.2. Financial performance
    • 6.3.7.3. Product benchmarking
    • 6.3.7.4. Strategic initiatives
  • 6.3.8. Accuray Incorporated
    • 6.3.8.1. Company overview
    • 6.3.8.2. Financial performance
    • 6.3.8.3. Product benchmarking
    • 6.3.8.4. Strategic initiatives
  • 6.3.9. Carthera
    • 6.3.9.1. Company overview
    • 6.3.9.2. Financial performance
    • 6.3.9.3. Product benchmarking
    • 6.3.9.4. Strategic initiatives
  • 6.3.10. Alpheus Medical Inc.
    • 6.3.10.1. Company overview
    • 6.3.10.2. Financial performance
    • 6.3.10.3. Product benchmarking
    • 6.3.10.4. Strategic initiatives
  • 6.3.11. Alpha Tau Medical Ltd
    • 6.3.11.1. Company overview
    • 6.3.11.2. Financial performance
    • 6.3.11.3. Product benchmarking
    • 6.3.11.4. Strategic initiatives
  • 6.3.12. Elekta
    • 6.3.12.1. Company overview
    • 6.3.12.2. Financial performance
    • 6.3.12.3. Product benchmarking
    • 6.3.12.4. Strategic initiatives
  • 6.3.13. IMRIS Inc.
    • 6.3.13.1. Company overview
    • 6.3.13.2. Financial performance
    • 6.3.13.3. Product benchmarking
    • 6.3.13.4. Strategic initiatives
  • 6.3.14. Medtronic
    • 6.3.14.1. Company overview
    • 6.3.14.2. Financial performance
    • 6.3.14.3. Product benchmarking
    • 6.3.14.4. Strategic initiatives
  • 6.3.15. Monteris
    • 6.3.15.1. Company overview
    • 6.3.15.2. Financial performance
    • 6.3.15.3. Product benchmarking
    • 6.3.15.4. Strategic initiatives
  • 6.3.16. Openwater
    • 6.3.16.1. Company overview
    • 6.3.16.2. Financial performance
    • 6.3.16.3. Product benchmarking
    • 6.3.16.4. Strategic initiatives
  • 6.3.17. Acoustic MedSystems, Inc.
    • 6.3.17.1. Company overview
    • 6.3.17.2. Financial performance
    • 6.3.17.3. Product benchmarking
    • 6.3.17.4. Strategic initiatives
  • 6.3.18. NaviFUS Corp
    • 6.3.18.1. Company overview
    • 6.3.18.2. Financial performance
    • 6.3.18.3. Product benchmarking
    • 6.3.18.4. Strategic initiatives
  • 6.3.19. Insightec
    • 6.3.19.1. Company overview
    • 6.3.19.2. Financial performance
    • 6.3.19.3. Product benchmarking
    • 6.3.19.4. Strategic initiatives
  • 6.3.20. Varian Medical Systems, Inc. (Siemens Healthineers)
    • 6.3.20.1. Company overview
    • 6.3.20.2. Financial performance
    • 6.3.20.3. Product benchmarking
    • 6.3.20.4. Strategic initiatives
  • 6.3.21. RefleXion
    • 6.3.21.1. Company overview
    • 6.3.21.2. Financial performance
    • 6.3.21.3. Product benchmarking
    • 6.3.21.4. Strategic initiatives
  • 6.3.22. MagnetTx Oncology Solutions Ltd.
    • 6.3.22.1. Company overview
    • 6.3.22.2. Financial performance
    • 6.3.22.3. Product benchmarking
    • 6.3.22.4. Strategic initiatives
  • 6.3.23. NICO Corporation (Stryker)
    • 6.3.23.1. Company overview
    • 6.3.23.2. Financial performance
    • 6.3.23.3. Product benchmarking
    • 6.3.23.4. Strategic initiatives
  • 6.3.24. Terumo Interventional Systems
    • 6.3.24.1. Company overview
    • 6.3.24.2. Financial performance
    • 6.3.24.3. Product benchmarking
    • 6.3.24.4. Strategic initiatives
  • 6.3.25. Boston Scientific Corporation
    • 6.3.25.1. Company overview
    • 6.3.25.2. Financial performance
    • 6.3.25.3. Product benchmarking
    • 6.3.25.4. Strategic initiatives
  • 6.3.26. Koninklijke Philips N.V.
    • 6.3.26.1. Company overview
    • 6.3.26.2. Financial performance
    • 6.3.26.3. Product benchmarking
    • 6.3.26.4. Strategic initiatives
  • 6.3.27. IBA Worldwide
    • 6.3.27.1. Company overview
    • 6.3.27.2. Financial performance
    • 6.3.27.3. Product benchmarking
    • 6.3.27.4. Strategic initiatives

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 U.S. Brain Tumor market, by Treatment Type 2024 - 2034 (USD Million)
• Table 4 U.S. Brain Tumor market, by Tumor Type 2024 - 2034 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 U.S. brain tumor market: Market snapshot
• Fig. 9 U.S. brain tumor market: Market segmentation
• Fig. 10 U.S. brain tumor market: Strategy framework
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 U.S. brain tumor market driver impact
• Fig. 14 U.S. brain tumor market restraint impact
• Fig. 15 U.S. brain tumor market porter's five forces analysis
• Fig. 16 U.S. brain tumor market PESTEL analysis
• Fig. 17 U.S. brain tumor market segment dashboard
• Fig. 18 U.S. brain tumor market: Tumor type movement Analysis
• Fig. 19 Malignant brain tumor market estimates and forecast, 2024 - 2034 (USD Million)
• Fig. 20 Non-malignant brain tumor market estimates and forecast, 2024 - 2034 (USD Million)
• Fig. 21 U.S. brain tumor market: Treatment type (malignant) movement Analysis
• Fig. 22 Surgery market estimates and forecast, 2024 - 2034 (USD Million)
• Fig. 23 Radiation therapy market estimates and forecast, 2024 - 2034 (USD Million)
• Fig. 24 Interventional device-based procedures market estimates and forecast, 2024 - 2034 (USD Million)
• Fig. 25 Chemotherapy market estimates and forecast, 2024 - 2034 (USD Million)
• Fig. 26 Targeted therapy market estimates and forecast, 2024 - 2034 (USD Million)
• Fig. 27 Tumor Treating Fields (TTF) market estimates and forecast, 2024 - 2034 (USD Million)
• Fig. 28 Laser Interstitial Thermal Therapy (LITT) market estimates and forecast, 2024 - 2034 (USD Million)
• Fig. 29 Surgically targeted radiation therapy market estimates and forecast, 2024 - 2034 (USD Million)
• Fig. 30 Catheter-based ultrasound thermal ablation market estimates and forecast, 2024 - 2034 (USD Million)
• Fig. 31 Focused Ultrasound (FUS) market estimates and forecast, 2024 - 2034 (USD Million)
• Fig. 32 Low-Intensity Focused Ultrasound (LIFU) market estimates and forecast, 2024 - 2034 (USD Million)
• Fig. 33 U.S. brain tumor market: Treatment type (non-malignant) movement Analysis
• Fig. 34 Surgery market estimates and forecast, 2024 - 2034 (USD Million)
• Fig. 35 Radiation therapy market estimates and forecast, 2024 - 2034 (USD Million)
• Fig. 36 Other monitoring devices market estimates and forecast, 2024 - 2034 (USD Million)